Procept BioRobotics: An Undervalued Surgical Robotics Growth Story

Avalon Capital Research93 FollowersFollow5ShareSavePlay(18min)Comment(1)SummaryPROCEPT BioRobotics is rated buy, offering a unique, FDA-cleared Aquablation platform for BPH, targeting a large, underpenetrated market.PRCT trades at 2.9x forward EV/2026E revenue, a deep discount to peers, despite 27-33% guided revenue growth and improving margins.A recent Q4 revenue miss and rebate changes triggered a 63% stock drop, but fundamentals remain strong with $286M cash and minimal dilution risk.2026 catalysts include EAU guideline upgrade, CPT code improvement, and the pivotal WATER IV FDA trial, supporting a base case for 84% upside.At Avalon Capital Research, we rate PROCEPT BioRobotics Corporation a BUY. PhonlamaiPhoto/iStock via Getty Images Investment Thesis When investors think of surgical robotics companies, Intuitive Surgical, Inc. (ISRG) is typically what comes to mind. ISRG built a $168B franchise on the ubiquitous da Vinci, and earned it by navigating theThis article was written byAvalon Capital Research93 FollowersFollowAt Avalon Capital Research, our mission is to deliver independent, actionable research on US-listed companies and market drivers. We believe investors deserve clarity, not noise, regarding earnings events, corporate strategy, and sector trends. Our motto is: Independent Research. Clear Insights. Trusted Analysis. In a crowded financial news landscape, we distinguish ourselves by combining institutional research with accessible digital publishing. We aim to provide high-quality analysis to both professional and retail investors, free from jargon, hype, or bias. We believe successful investing begins with clarity, which means focusing on what matters, filtering out distractions, and grounding insights in data. Our commitment is to offer perspectives investors can trust and apply, regardless of experience level.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.